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A.2 Structure and Function of Human Proteinase Inhibitors 
Measurement of the Proteinase Inhibitors of the 
Bovine Pancreas by Radioimmunoassay* 
E. FINKf and L . J . GREENEf t 
BO/INE pancreas contains two different Polypeptide trypsin inhibitors, Kunitz inhibitor^ 6 ' 8^ 
anc Kazal inhibi tor / 3 ' 7 ) Some of their properties are summarized in Table 1. Both inhibitors 
arefound in the bovine pancreatic tissue in approximately equimolar concentrations/2^ yet 
onV the Kazal inhibitor is detectable in pancreatic juice. 
\s the first Step in the study of the physiological role of these two Polypeptide inhibitors we 
ha^ e set up a radioimmunoassay for each inhibitor, because this analytical method provides 
boh specificity and high sensitivity. In this communication we describe the labelling of Kazal 
am Kunitz inhibitors with 1 2 5 I using the lactoperoxidase method/ 9 ' 1 2 ^ present a radio-
imnunoassay for each inhibitor and report the application of the assays in an in vitro secretion 
stuly of bovine pancreas. 
TABLE 1. BOVINE PANCREATIC TRYPSIN INHIBITORS 
Kazal Kunitz 
Trypsin inhibition + + 
Acrosin inhibition + + 
Plasmin inhibition - + 
Chymotrypsin inhibition - + 
Kallikrein inhibition - + 
Amino acids/molecule 56 58 
Molecular weight 6161 6518 
Isoelectric point 4.8,5.2,5.9 10.5 
Present in: 
pancreatic tissue + (~1.5X) +(~1X) 
pancreatic juice + — 
RADIOIODINATION 
Tie procedure described by Thoreil and Johansson for the iodination of Polypeptide 
hornones using lactoperoxidase^12) was employed for the 1 2 5 Mabel l ing of Kunitz and Kazal 
üüir i tors / 1 ) Iodination and purification procedures were identical for both inhibitors. Table 2 
presents the experimental conditions by which the incorporation of 0.4nmole 1 2 5 I per 
Hesearch carried out at Brookhaven National Laboratory under the auspices of the U.S. Atomic Energy 
Ccmnission. 
fyisiting Biochemist at Brookhaven National Laboratory, 1972-1974. Supported by Deutsche 
Forschungsgemeinschaft. Present address: Institut für Klinische Chemie und Klinische Biochemie der 
Urivtrsität München, D-8 München 2, Nussbaumstr. 20, Germany. 
t'Brookhaven National Laboratory, Upton, N.Y. 11973, USA. 
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TABLE 2. ENZYMATIC IODINATION OF BOVINE 
PANCREATIC TRYPSIN INHIBITORS 
(a) Na 1 2 5 I , 1 mCi, pH 8-10 10 Ml 
(b) Potassium phosphate buffer, 0.4 M, pH 6.1 10 MI 
(c) Inhibitor, 4 Mg in H 2 O 5 Ml 
(d) Lactoperoxidase (Calbiochem) 1 Mg in H 2 O 4 MI 
(e) H 2 0 2 , 1 Mg in five 2 M ! additions at 30 
min intervals 10 Ml 
(0 Reaction stopped after 2.5 hr by addition of 
20 M1 NaN 3 (0.3%), 200 MI Nal (0.1%) and 
600 M ! G-50 elution buffer 
FRACTION NUMBER (0.8 ml/FRACT10N) 
FIG. 1. Isolation of 1 2 5I-Kazal inhibitor by gel filtration. The reaction mixture was applied to 
a Sephadex G-50 fine column, 0.6 X 120 cm, equilibrated and developed at 4°C with 0.05 M 
Tris-HCl buffer, pH 8.6, containing 0.5% bovine serum albumin, 0.5 M KCl and 0.02% NaN3. 
The numbers indicate the percentage of recovered radioactivity in each effluent peak. 
1 nmole inhibitor was achieved. The number of iodine atoms incorporated per molecule 
inhibitor can be controlled by altering the amount of inhibitor in the reaction mixture while 
keepingall other parameters unchanged. 
The reaction mixture was immediately subjected to gel filtration on Sephadex G-50 fine 
(Fig. 1). The iodinated inhibitor was eluted as a symmetrical peak in fractions 27—33, the same 
volume in which unlabeled inhibitor was eluted. The gel filtration Step effectively separated the 
radioactive inhibitor from high molecular weight iodinated material (fractions 16—25), 
presumably derived from the lactoperoxidase preparation, and from low molecular weight 
radioactive material (fractions 41—46), which is probably free 1 2 5 I . Iodinated Kunitz and 
Kazal inhibitor preparations were stored at 4°C in the Sephadex G-50 elution buffer. They were 
generally rechromatographed on Sephadex G-50 prior to a radioimmunoassay experiment. 
Upon rechromatography most of the iodinated material was eluted in the position of the 
inhibitor, a small amount of the radioactivity appeared in the low molecular weight region. The 
preparations were generally retained for up to eight weeks for use in radioimmunoassay. 
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i i I I I I I 1 
39 78 156 312 625 I 2500 I 
1250 5000 
BOVINE P ST I (KAZAL) , p i c o g r a m s 
FIG. 2. Dose-response curve for the radioimmunoassay of Kazal inhibitor. Each tube contained 
100 /ul 125I-inhibitor (25,000 cpm), 200 ßl Standard düuent (SD: 0.05 M potassium phosphate 
buffer pH 7.6, 0.25% bovine serum albumin, 0.02% NaN3), 100 pl unlabeled inhibitor dissolved 
in SD, 100 jul of antiserum at a dilution sufficient to bind 50% of the labeled inhibitor. After 
48 hr at 21°C the bound inhibitor was separated by the addition of 100 /ulgoat antirabbit IgG 
serum (1:30) and 100 ßl rabbit serum (1:600) followed by incubationat 4°C for 12 hr. The 
radioactivity of the precipitate was counted after centrifugation. 
RADIOIMMUNOASSAY PROCEDURE 
Antiserum to Kunitz inhibitor was prepared from rabbits immunized with the antigen in 
incomplete Freund's adjuvant; antiserum to Kazal inhibitor was prepared from rabbits with 
Kazal inhibitor coupled to human albumin; both antisera were used without any further 
purification. The double antibody method was employed for the radioimmunoassays using goat 
antirabbit IgG serum as the second antibody to separate bound inhibitor from free inhibitor/ 4^ 
Studies of the binding of labeled inhibitor showed that 85—90% of the radioactivity in each 
1 2 5 1 inhibitor preparation was bound by the antibody. A Standard curve for the radioimmuno-
assay of Kazal inhibitor is given in Fig. 2. Linearization of the dose—response curve was 
achieved for either antigen—antibody System by plotting the logit transform of the response 
versus log dose of an t igen / 1 0 ' 1 1 ) Both assays were sensitive to 0.04—0.08 ng inhibitor and 
were generally used in the ränge of 0.1—5 ng inhibitor per tube with deviations of replicates 
±10% or less. The experimental conditions for incubation and Separation of bound antigen are 
given in the legend to Fig. 2. We have not attempted to increase the sensitivity of the assay, 
although it is probable that sensitivity could be increased by using inhibitor preparations of 
higher specific radioactivity. The System described here is reasonably stable and provides high 
sensitivity. 
There is no cross-reactivity detectable between the Kunitz and the Kazal inhibitor— 
antiserum Systems. Neither iodinated inhibitor is bound by the antiserum to the other inhibitor 
under the conditions of the double antibody radioimmunoassay. 800-fold molar excess of one 
inhibitor had no effect on the quantitative determination of the second inhibitor. Trypsin 
interfered with the assays of both inhibitors by reducing the amount of iodinated inhibitor 
bound to the antibody. This suggests that the inhibitor—trypsin complex is less effectively 
bound to the antibody than the inhibitor. For this reason, samples which might have contained 
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30 60 120 180 
INCUBATION TIME (min) 
FIG. 3. Kinetics of release of amylase (A A), and of Kazal (o o) and Kunitz inhibitors 
(• •) from bovine pancreatic slices in the presence (+ C) and absence (- C) of 10"6 M 
carbamylcholine in the incubation medium. 
trypsin were treated with 2.5% trichloroacetic acid (TCA) to precipitate the trypsin while the 
inhibitors remain in Solution/ 7 ^ The recovery of each iodinated inhibitor added to the 
pancreatic juice or homogenates of pancreas was 70—80% after treatment with TCA. 
IN VITRO SECRETION STUDY OF BOVINE PANCREAS 
The RIAs of Kazal and Kunitz inhibitors were employed for the study of the secretion of 
bovine pancreas/5) Slices of fresh bovine pancreatic tissue were placed in Krebs-Ringer buffer 
containing glucose and amino acids and washed repeatedly with the same Solution. Two sets of 
slices were incubated in the Krebs-Ringer buffer at 37°C; the medium of one set was 10~ 6 M in 
carbamylcholine, a secretagogue which is a choline-esterase-resistant analog of acetylcholine. At 
the times shown in Fig. 3 (abscissa), aliquots of the incubation media were removed and 
replaced by fresh medium. After the incubation the tissue slices were homogenized in water. Al l 
samples and the homogenates were assayed for their concentration in amylase by a Photometrie 
method and for their concentrations in Kazal and Kunitz inhibitors by radioimmunoassay. 
Figure 3 shows the kinetics of release of the three substances. 
Two facts confirm the secretory nature of Kazal inhibitor. First, the secretagogue 
carbamylcholine stimulates its release into the medium. Second, the kinetics of release of Kazal 
inhibitor into the medium is identical with those of amylase, whose secretory nature is well 
known. 
MEASUREMENT OF THE PROTEINASE INHIBITORS OF THE BOVINE PANCREAS 215 
The release of Kunitz inhibitor into the medium is completely different from that of Kazal 
inhibitor and is probably due to cell death. By contrast with Kazal inhibitor the release of 
Kunitz inhibitor is not stimulated significantly by carbamylcholine, nor does it parallel that of 
amylase, thus demonstrating the non-secretory nature of Kunitz inhibitor. 
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